Second-generation antipsychotics in the emergency care setting. A prospective naturalistic study

By Raja M.   Azzoni A.  

General Hospital Psychiatry, Vol. 22, Iss. 2, 2000-04 ,pp. : 107-114

Elsevier

Access to resources Recommend Favorite

Second-Generation Antipsychotic Medications and Risk of Pneumonia in Schizophrenia

By Kuo Chian-Jue   Yang Shu-Yu   Liao Ya-Tang   Chen Wei J.   Lee Wen-Chung   Shau Wen-Yi   Chang Yao-Tung   Tsai Shang-Ying   Chen Chiao-Chicy  

Schizophrenia Bulletin, Vol. 39, Iss. 3, 2013-05 ,pp. : 648-657

Oxford University Press

Access to resources Recommend Favorite

Money matters: does the reimbursement policy for second-generation antipsychotics influence the number of recorded schizophrenia patients and the burden of stigmatization?

By Kiejna Andrzej   Misiak Blazej   Zagdanska Marta   Drapala Jaroslaw   Piotrowski Patryk   Szczesniak Dorota   Chladzinska-Kiejna Sylwia   Cialkowska-Kuzminska Magdalena   Frydecka Dorota  

Social Psychiatry and Psychiatric Epidemiology, Vol. 49, Iss. 4, 2014-04 ,pp. : 531-539

Springer Publishing Company

Access to resources Recommend Favorite

Flupentixol use and adverse reactions in comparison with other common first- and second-generation antipsychotics: data from the AMSP study

By Grohmann R.   Engel R.   Möller H.-J.   Rüther E.   Velden J.   Stübner S.  

European Archives of Psychiatry and Clinical Neuroscience, Vol. 264, Iss. 2, 2014-03 ,pp. : 131-141

Springer Publishing Company

Access to resources Recommend Favorite

Metabolic Risk with Second-Generation Antipsychotic Treatment: A Double-Blind Randomized 8-Week Trial of Risperidone and Olanzapine

By Kelly Deanna  

Annals of Clinical Psychiatry (after Jan 1, 2004), Vol. 20, Iss. 2, 2008-05 ,pp. : 71-78

Informa Healthcare

Access to resources Recommend Favorite